The US-China technology rivalry is expanding into biotechnology, with export controls and investment restrictions opening a new front in strategic competition. East Asia’s push for biotech autonomy is gaining momentum — but it risks slowing innovation. A turning point came in January 2025, when the US restricted China’s access to advanced biotechnology equipment, including high-parameter […]The post East Asia’s biotech autonomy push is already stunting innovation appeared first on Asia Times.